Use of C1 Inhibitor for the Prevention of Ischemia-Reperfusion Injury
AssigneePharming Intellectual Property B.V.
InventorsMaurice Mannesse, Johannes Henricus Nuijens, Frank Pieper, Maria Grazia De Simoni, Gijsbertus Johannes Ziere
Life of this patent
Estimating the term…
Abstract
The present invention relates to the therapeutic and prophylactic use of C1 inhibitor for preventing, reducing and treating ischemia and reperfusion injury. The C1 inhibitor of the present invention is still therapeutically effective when administered after an ischemic period and reperfusion and therefore particularly useful for unforeseen occurrences of ischemic reperfusion such as e.g. a stroke.
Claims27
1-20. (canceled)
A method for preventing, reducing or treating ischemia and/or reperfusion injury in a subject, comprising administering to a subject in need thereof, at least 10 minutes after an ischemic period or after start of reperfusion, a pharmaceutical composition comprising a C1 inhibitor characterized by a plasma half life shorter than 6 hours.
A method for preventing, reducing or treating ischemia and/or reperfusion injury in an organ being transplanted to a subject, comprising providing to the organ, prior to transplant, and before an ischemic period or reperfusion of the organ, a pharmaceutical composition comprising a C1 inhibitor that is characterized by a plasma half life of less than 6 hours, thereby preventing, reducing or treating said ischemia and/or reperfusion injury of the organ.
Dependencies are inferred from the claim text.